Carrimycin Biosynthetic Gene Cluster Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing carrimycin, a 16-membered macrolide antibiotic, face challenges in efficiently synthesizing and modifying the antibiotic biosynthetic gene clusters to enhance its antibacterial activity and yield, while maintaining safety and minimizing adverse reactions.
Innovation Solution
The disclosure provides a comprehensive biosynthetic gene cluster of carrimycin comprising 44 gene open reading frames, including polyketide synthase, glycosyl synthesis, resistance, and regulation genes, along with specific amino acid sequences for enzymes involved in its biosynthesis, allowing for genetic manipulation to modify and enhance the antibiotic's production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce carrimycin, then the production process is simple and convenient, but the antibacterial activity and yield are insufficient
Solution Approach 1:
The biosynthetic gene cluster is divided into multiple functional modules including polyketide synthase genes (orf10-14), glycosyl synthesis genes (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41), glycosyl transfer genes (orf7, 8, 30-32 and 40), resistance genes (orf3 and 25), and regulation genes (orf2, 23, 27 and 42). This segmentation allows targeted modification of specific genes to enhance yield and antibacterial activity without redesigning the entire production system.
Solution Approach 2:
The patent modifies parameters of the gene cluster by changing gene expression levels, altering enzyme specificity through point mutations, and adjusting regulatory gene products. These parameter changes enable optimization of carrimycin production yield and enhancement of antibacterial activity while maintaining the overall simplicity of the fermentation process.
2Reliability
If conventional methods are used to produce carrimycin, then the production process is simple and convenient, but the antibacterial activity is insufficient
Solution Approach 1:
The patent applies local quality modification by targeting specific genes within the cluster for enhancement. For example, modifying polyketide synthase genes (orf10-14) to improve core antibiotic structure, modifying glycosyl transfer genes (orf7, 8, 30-32 and 40) to optimize glycosyl group attachment, and adjusting regulation genes (orf2, 23, 27 and 42) to control expression levels. This localized modification approach enhances antibacterial activity without requiring complete system redesign.
3Productivity
If gene engineering is used to enhance carrimycin properties, then antibacterial activity and yield are improved, but the complexity of the production system increases
Solution Approach 1:
The patent merges multiple functional genes into a single integrated biosynthetic gene cluster located on a chromosomal region. This consolidation allows coordinated expression of polyketide synthase, glycosyl synthesis, glycosyl transfer, resistance, and regulation functions, achieving enhanced yield and antibacterial activity while maintaining production process simplicity through a unified genetic system.
4Ease of manufacture
If chemical contamination is used in production, then traditional chemical synthesis can be employed, but energy consumption increases and contamination occurs
Solution Approach 1:
The patent replaces chemical synthesis methods with biological synthesis using engineered microorganisms. The biosynthetic gene cluster enables metabolic pathways to produce carrimycin through enzymatic reactions, eliminating the need for energy-intensive chemical synthesis steps and avoiding chemical contamination. This biological approach maintains ease of manufacture through fermentation processes while significantly reducing energy consumption and environmental harm.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the modification of carrimycin's biosynthetic pathway to improve its antibacterial activity, yield, and safety profile, facilitating the development of novel antibiotics with enhanced properties.
Implementation Method 1
Macrolides are formed through carrying out a continuous condensation reaction to catalyze some simple carboxylic acid molecules by PKS composed of modular structures
Implementation Method 2
The glycosyl groups are undertaken by glycosyl synthesis and transfer related enzymes
Implementation Method 3
The gene cluster contains 5 orfs encoding polyketide synthase, 9 orfs related to polyketone synthesis extension unit and modification, 16 orfs related to glycosyl synthesis and 6 orfs related to glycosyl transfer
Data Source
AI summary
The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4″-mycaroseglucoside isovaleryl transferase gene orf (orf44).